Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : PharmaMar | IrsiCaixa
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 09, 2025
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : PharmaMar | IrsiCaixa
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 30, 2023
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The final results of APLICOV-PC study (Phase I-II), demonstrate the safety of Aplidin (plitidepsin) use in patients with COVID-19 and postulate a positive therapeutic impact on the evolution of the disease.
Product Name : Aplidin
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 01, 2022
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Apices Soluciones
Deal Size : Inapplicable
Deal Type : Inapplicable
Extension Study in a Cohort of Adult Patients With COVID-19 Infection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 16, 2021
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Apices Soluciones
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Spain's PharmaMar Says Covid-19 Treatment Drug Shows Clinical Efficacy in Trials
Details : The APLICOV-PC study evaluated three cohorts of hospitalized patients with mild, moderate or severe disease, with three different dose levels of plitidepsin (1.5mg - 2.0mg - 2.5mg), administered on three consecutive days.
Product Name : Aplidin
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 26, 2021
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2021
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pharma Mar has obtained MHRA approval for UK patients to participate in the Phase III NEPTUNO clinical trial, which will determine the efficacy of Aplidin® for the treatment of hospitalized patients with moderate COVID-19 infection.
Product Name : Aplidin
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 17, 2021
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Apices Soluciones
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PharmaMar’s cancer drug Aplidin (plitidepsin) has demonstrated ‘potent preclinical efficacy’ against SARS-CoV-2, the virus which causes COVID-19. Aplidin inhibits the eEF1A protein, which is associated with the SARS-CoV-2 virus.
Product Name : Aplidin
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 26, 2021
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Apices Soluciones
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Icahn School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Plitidepsin shows potent anti-viral effect in preclinical models of original SARS-CoV-2 as well as the new mutant U.K. strain, and by inhibiting a key host protein, has the potential to have antiviral activity against other future mutations and viruses.
Product Name : Aplidin
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 25, 2021
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Icahn School of Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmaMar Plans Phase III Trial of Cancer Drug for COVID-19, Shares Jump
Details : There was a substantial reduction in viral load and the C-reactive protein (CRP) in patients, and that 80.7% of patients had been discharged before the 15th day of hospitalisation, and 38.2% before the eighth day.
Product Name : Aplidin
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 16, 2020
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable